1. Home
  2. RARE vs EVTC Comparison

RARE vs EVTC Comparison

Compare RARE & EVTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RARE
  • EVTC
  • Stock Information
  • Founded
  • RARE 2010
  • EVTC 1988
  • Country
  • RARE United States
  • EVTC United States
  • Employees
  • RARE N/A
  • EVTC N/A
  • Industry
  • RARE Biotechnology: Pharmaceutical Preparations
  • EVTC EDP Services
  • Sector
  • RARE Health Care
  • EVTC Technology
  • Exchange
  • RARE Nasdaq
  • EVTC Nasdaq
  • Market Cap
  • RARE 2.6B
  • EVTC 2.2B
  • IPO Year
  • RARE 2014
  • EVTC 2013
  • Fundamental
  • Price
  • RARE $30.04
  • EVTC $32.07
  • Analyst Decision
  • RARE Strong Buy
  • EVTC Hold
  • Analyst Count
  • RARE 14
  • EVTC 5
  • Target Price
  • RARE $86.64
  • EVTC $39.00
  • AVG Volume (30 Days)
  • RARE 1.8M
  • EVTC 328.7K
  • Earning Date
  • RARE 11-04-2025
  • EVTC 11-05-2025
  • Dividend Yield
  • RARE N/A
  • EVTC 0.62%
  • EPS Growth
  • RARE N/A
  • EVTC 102.95
  • EPS
  • RARE N/A
  • EVTC 2.13
  • Revenue
  • RARE $610,159,000.00
  • EVTC $886,589,000.00
  • Revenue This Year
  • RARE $19.72
  • EVTC $9.23
  • Revenue Next Year
  • RARE $23.29
  • EVTC $4.84
  • P/E Ratio
  • RARE N/A
  • EVTC $15.03
  • Revenue Growth
  • RARE 26.77
  • EVTC 12.93
  • 52 Week Low
  • RARE $25.81
  • EVTC $31.41
  • 52 Week High
  • RARE $58.00
  • EVTC $38.56
  • Technical
  • Relative Strength Index (RSI)
  • RARE 51.17
  • EVTC 31.35
  • Support Level
  • RARE $29.60
  • EVTC $31.95
  • Resistance Level
  • RARE $31.70
  • EVTC $33.97
  • Average True Range (ATR)
  • RARE 1.22
  • EVTC 0.66
  • MACD
  • RARE 0.15
  • EVTC -0.15
  • Stochastic Oscillator
  • RARE 60.51
  • EVTC 4.79

About RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

About EVTC Evertec Inc.

Evertec Inc is a transaction processing business in Latin America and the Caribbean. Its business segments are Merchant Acquiring, Payment Services - Puerto Rico & Caribbean, Latin America Payments and Solutions, and Business Solutions which derive maximum revenue. The company serves a diversified customer base of financial institutions, merchants, corporations, and government agencies with mission-critical technology solutions that enable them to issue, process, and accept transactions securely. It derives maximum revenue from Latin America Payments and Solutions. Geographically, it operates in Puerto Rico, Caribbean, and Latin America.

Share on Social Networks: